Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Semaglutide B, mL · 2 trials · 3 indications
Measured in hours\*nanomoles per liter (h\*nmol/L).
Measured in nanomoles per liter (nmol/L).
Measured in h\*nmol/L
Measured in nmol/L
| Arm | Type | Description |
|---|---|---|
| Sequence A | EXPERIMENTAL | Participants will be administered a single subcutaneous (s.c.) dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 2. |
| Sequence B | EXPERIMENTAL | Participants will be administered a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 2. |
| Semaglutide B, 1.34 mg/mL followed by Semaglutide D, 1.0 mg/mL | EXPERIMENTAL | - |
| Semaglutide D, 1.0 mg/mL followed by Semaglutide B, 1.34 mg/mL | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Semaglutide B, 1.34 mg/mL | DRUG | Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously. |
| Semaglutide B, 0.68 mg/mL | DRUG | Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously. |
| Semaglutide D, 1.0 mg/mL | DRUG | Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously. |
Inclusion Criteria: * Male or female * Aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 20.0 and 29.9 kilograms per meter square (kg/m\^2) (both inclusive) Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pr...
Semaglutide B is an investigational small molecule being studied for Type 2 Diabetes Mellitus and in healthy volunteers. It is in Phase 1 clinical development by Novo Nordisk A/S. The drug is not approved and remains under investigation for its potential use in these metabolic conditions.
Semaglutide B is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the stock exchange under the ticker NVO. The company is conducting early-stage clinical trials to evaluate this investigational small molecule for Type 2 Diabetes Mellitus.
Semaglutide B is currently in Phase 1 clinical development. It has completed three Phase 1 trials with a total enrollment of 90 participants. The drug is investigational and has not received approval, though it has been granted accelerated approval designation by the FDA.
Semaglutide B has completed three Phase 1 trials: NCT05232708, a comparability study of two forms of semaglutide in healthy volunteers in the UK; NCT05689099, a comparability study of two concentrations in the US; and NCT06642584, a study of new protein-based tablets in healthy men in Canada.
Semaglutide B is a distinct investigational drug being developed by Novo Nordisk. While it shares a name with the approved medication semaglutide, Semaglutide B is a separate small molecule in early clinical development for Type 2 Diabetes Mellitus and has not been approved for any use.